A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy

NCT03499834 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ivy Life Sciences, Co., Ltd

Collaborators